Clinical Implications for Intervention
|
|
- Lambert Lawson
- 6 years ago
- Views:
Transcription
1 Hereditary Breast and Ovarian Cancer Syndromes: Clinical Implications for Intervention Muhieddine Seoud, MD, FACOG, FACS American University of Beirut Medical Center MEMAGO 1rst meeting, Ankara, March 2016
2
3 Hereditary breast and ovarian cancer (HBOC): Objectives 1. Review the changing prevalence of HBOC syndromes 2. Emphasize the importance of history taking in familial cancer syndromes 1. Identify and select appropriate genetic counseling/testing/companion diagnostics to evaluate germline and somatic mutations of such patients 1. Present available data on lifetime risk of various mutations in various cancers 1. Summarize the current recommendations for risk reducing interventions 1. Take home message
4 HBOC: Facts The hallmarks of hereditary cancer syndromes: 1. Multiple affected family members 2. Early age of onset 3. Multiple and/or bilateral primary cancers Multiple syndromes associated with increase risks 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
5 Case report: Ms. C.S. : 3 cancers in one, all missed 52 years old single female presenting with abdominal carcinomatosis Sister had serous ovarian cancer at age 43 At age 47: Myomectomy for an 18 cm myoma Left 2 cm breast mass: no Work up and no FU 6 months later, left triple negative breast cancer: Lumpectomy and SLN chemo/radio/no tamoxifen Right adnexal mass observed stable At age 52: Abdominal carcinomatosis bilateral ovarian cancers stage IIIC Referred for management 2 cm thyroid nodule discovered FNA thyroid papillary cancer
6
7 Case report: Ms. N.S.
8 Patient Cancer Family History No Yes Does the family history raise red flags? No Yes: Hereditary Cancer Testing Negative or VUS Positive Mutation General Population Familial Risk Hereditary Risk
9 HBOC: Facts ~ 20 30% of patients carry a germline mutations in DNA repair pathways 8 10% have a family history of the ds and may carry mutations in BRCA ½ 8 10% without family history of the ds and may carry mutations in BRCA ½ ~ 22% of patients in a breast surgery practice may be appropriate for BRCA testing Tumors may carry somatic mutations in BRCA BRCAness: Tumors may carry mutations in other proteins associated with DNA repair Caveats: 1. Unknown risk from specific mutations: (VUS) 2. Unknown impact on prognosis & response rates for some of these mutations 1. Alsop K et al. J Clin Oncol 2012;30: Liu et al. Clin Cancer 2014; Lodhia K et al. Ann Oncol 2015;26;ii31 Pennongton KP et al. Clin Cancer Res 2014;20:764 75
10 HBOC: Rates of VUS decreasing 1. Alsop K et al. J Clin Oncol 2012;30: Liu et al. Clin Cancer 2014; Lodhia K et al. Ann Oncol 2015;26;ii31 Pennongton KP et al. Clin Cancer Res 2014;20:764 75
11 HBOCS: Patients with an increased likelihood of having an inherited predisposition Women AFFECTED with: 1. High grade EOC/TC/PPC 2. BCA 45 years 3. BCA with: close relative b with BCA 50 yrs close relative b with EOC/TC/PPC 4. BCA 50 years with a limited family history c 5. BCA with 2 close relatives b with BCA at any age 6. BCA with 2 close relatives b with pancreatic cancer, prostate cancer (GS 7) 7. 2 breast 1ries, with the 1rst dx < 50 ys 8. Triple negative BCA 60 years 9. BCA and Ashkenazi Jewish ancestry 10. Pancreatic cancer with 2 close relatives b with BCA, prostate cancer (GS 7) b Close relative is defined as a first degree (parent, sibling, offspring), second degree (grandparent, grandchild, uncle, aunt, nephew, niece, half sibling) or third degree (first cousin, great grandparent or great grandchild) relative c Limited family history includes fewer than 2 first or second degree female relatives of female relatives surviving beyond 45 years.
12 HBOCS: Patients with an increased likelihood of having an inherited predisposition Women UNAFFECTED with cancer, but with: A 1rst degree or several close relatives that meet one of the above criteria A close relative b carrying a known BRCA1 or BRCA2 mutation A close relative with male breast cancer b Close relative is defined as a first degree (parent, sibling, offspring), second degree (grandparent, grandchild, uncle, aunt, nephew, niece, half sibling) or third degree (first cousin, great grandparent or great grandchild) relative.
13 Hereditary susceptibility to ovarian/breast cancer 2002 BRCA2 (30%) Lifetime risk 15-30% BRCA1 (65%) Lifetime risk 30-60% HNPCC (7%) Hereditary (10%) Sporadic (90%) Rebbeck TR, Lynch HT, et al. NEJM 2002
14 Summary of Mutation Carriers: GOG 218 and % of mutation carriers had mutations in non BRCA 1/2 genes
15 Summary of Cancer Associated Mutations: GOG 218 and
16 Each cancer site is associated with multiple hereditary cancer syndromes: 23 Genes panel: APC, ATM, BARD1, BMPRIA, BRCA1, BRCA2, BRIP1, CDKN2A, CDK4, CHECK2, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTNE, RAD1C, RAD1D, SMAD4, STK11 and TP53
17 High Risk 3 x higher > general population Absolute risk ~ > 5% Multiple supporting studies Elevated risk Risk Does not meeting HR criteria Single study Contradictory data
18 HBOCS: Facts Women with Lynch HNPCC syndrome: Mutations in DNA mismatch repair genes: MLH1, MSH2, MSH6, or PMS2 MSI 25 50% lifetime risk of colorectal cancer (lower than male counterparts) Cancer Lifetime Risk MLH1 MSH2 MSH6 PMS2 Endometrial 20 54% 21 49% 16 71% 15% OVC/FT/PC by age % % % small 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
19 HBOCS: Facts Cowden syndrome Germline mutations in the PTEN gene 19 28% risk of endometrial cancer by age 70 True risk higher with an intact uterus 50% risk of breast cancer 3 10% risk of thyroid cancer 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
20 HBOCS: Facts Li Fraumeni syndrome P 53 mutation carriers 60% lifetime risk of breast cancer Sarcomas, brain, and adrenocortical carcinomas, etc.. 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
21 HBOCS: Facts Peutz Jeghers syndrome Less common Mutations in STK11/LKB1 gene 10% risk of cervical (adenoma malignum) 21% risk of ovarian (sex cord stromal tumors) 50% risk of breast cancers Other cancers: colon, pancreas, endometrium, gastric.. 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
22 HBOCS: Facts: Other genes BRIP1, RAD51D, and RAD51C: a lifetime risk of 10 15% PALB2 mutations: a clear increased RR has not been established DICER1: Sertoli Leydig tumors SMARCA4: ovarian small cell carcinoma List of genes associated with BCA and OCA will continue to increase 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
23
24 More Than BRCA1/2? The concept of BRCA ness Breast cancer : Basal phenotype Triple negative as an imperfect surrogate Ovarian cancer Particularly high grade serous Many of these patients may have dysregulation of BRCA1/2 The Cancer Genome Atlas (CGA) defect in the HR pathway in 50% of 489 tumors The Cancer Genome Atlas Network. Nature. 2011;474(7353):
25 The Cancer Genome Atlas (CGA) Network: 50% of Serous OVC have Germline or somatic HR defects
26 BRCA function BRCA RAD51C Normal DNA Double Strand DNA breaks Loss of BRCA function P 53 P 53 Cell Cycle arrest: Apoptosis Proliferation
27 Tumor selective Synthetic Lethality Endogenous DNA Damage (SS breaks: SSBs) PARP inhibition DNA DSbs accumulate with normal DNA replication HR Functional HR pathway (ie, BRCA wild type in normal cell) HR mediated DNA repair Cell survival NHEJ HR deficciency tumor cell (ie, BRCA mutated) Apoptosis: cell death Impaired HR mediated DNA repair Lord CJ et al. Ann Rev Med 2015;66: Iglehart JD et al NEJM 2009;361:189 91
28 BRCA 1 and BRCA 2 BRCA1 and BRCA2 mutations: 1. AD, highly penetrant, germline mutations on chromosomes 13, and 17 Lifetime risk varies among different populations: 1. Penetrance 2. Risk modifiers Different types of cancer and age of onset depending on: 1. gene gene interactions: Position of the mutation in the BRCA1 or BRCA2 gene Genetic variation in other genes 2. gene environment interactions: Age/Hormonal or reproductive factors/lifestyle factors The prevalence in the general population of European ancestry is ~ 0.25 % Increased prevalence in individuals of Norwegian, Dutch, and Icelandic ancestry Founder effect : The prevalence varies among ethnic groups and geographic area
29 Ovarian Cancer: Risk Factors Relative Risk Lifetime Probability No risk factors % (~ 1/72) Familial ovarian cancer 30 to 50% 2 or 3 relatives with ovarian cancer % (15% if 1 ) 1 relative with ovarian cancer % (5% if 1 ) Infertility 2.8 Nulligravity 1.6 HRT 1.27 Past pregnancy % Tubal ligation 0.59 Past oral contraceptive use % Past breast feeding 0.81
30 BRCA 1 and BRCA 2 mutations in ethnic lebanese Arab women with high risk hereditary breast cancer: Saghir N, Zgheib N, Seoud M et al.. Oncologist Lebanese women with breast cancer ( ) High risk of carrying BRCA1 or BRCA2 mutations young age positive family history (FH) of breast or ovarian cancer Despite high percentage of breast cancer in young women of Lebanese and Arab descent Prevalence of deleterious BRCA is lower than expected Doesn t support the hypothesis that BRCA mutations alone as a cause Oncologist 2015;20:357 64
31 HBOC: BRCA 1 and 2 carriers and the Lifetime risk of subsequent cancers Depends on the data base and ethnic background Cancer By age 70 Lifetime Risk BRCA 1 BRCA 2 Wild type Breast 65 85% 45 85% 1/7 8 (12%) OVC/FT/PC 39 46% 10 27% 1/72 (1.8%) 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
32 HBOC: BRCA 1 and 2 carriers and the Lifetime risk of subsequent cancers Depends on the data base and ethnic background Syndrome/Gene Clinical Mutation positivity rate Life time OC risk Other Features BRCA % % OC at earlier age (50) BRCA 2 1 6% % Lynch Syndrome 2,3 < 1% 3 14 % OC at same age as general population (60) OC at earlier age (43 50) Endometrial and colon cancer risks are higher RAD51C 4,7 1.3 % (RR 6 8) % RAD51D % (RR 6 9) % BRIP % (RR 8) %
33 Mutations Dramatically increase the risk of developing cancer Data From Myriad Genetic R
34 HBOCS: Genetic Testing Debate Changing Landscape Understanding of genetic predisposition for cancers is changing : from individual genes and syndromes to multiplex testing for a number of cancer susceptibility genes Expression profiling/ IHC Evolving use of BRCA1/2 testing vs. panel tests with expanded number of genes Such multiplex panels can be chosen based upon: Particular cancer patterns in families Ethnicity: Norwegian, Dutch, Icelandic, French Canadians, Hispanic, etc. Multiple genomic platforms Sequencing Clinical correlations is not always validated/ Could be used to identify appropriate clinical trials 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
35 HBOCS: Genetic Testing Debate Changing Landscape Single gene testing Traditional Sanger Multigene panel Massive parallel sequencing Sequencing approach High throughput Low throughput Lower cost for multiple genes High cost for multiple genes Misses structural rearrangements Better assessment of rearrangements Large number of VUS VUS, variants of uncertain significance
36 HBOCS: Genetic testing Things to consider 1. Increase in complexity of testing technology 1. Uncertainty in the interpretation of the results 2. Range of potentially identifiable cancer risk 3. Need for evaluating the likelihood of of a hereditary cancer syndrome Choosing the appropriate test/panel, and interpreting the result, all clearly argue that the first step in patient assessment should be genetic counseling 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
37 HBOCS: Genetic counseling Assessment for the presence of an inherited cancer syndrome Education Counseling Evaluation of available tumor by IHC and MSI (somatic mutations) Genetic counselor or others with expertise in cancer genetics Germline genetic testing 1. Ohio Cancer Incidence Surveillance System, Ohio Department of Health, Anderson MR et al. Cancer 2008;113: Myers ER et al. Evidence Report Technology Assessment 2006 full report Cancer Research UK. year
38 Ovarian cancer STIC in BRCA mutated and non mutated patients ~ 60% of patients with BRCA mutation undergoing RR-BSO had HG STIC Although STIC is capable of metastasizing (i.e. cannot be considered CIS), compelling evidence for a tubal origin of BRCA+ HGSC has accumulated over the past decade [2,3] HG STIC is not only reported in BRCA+ pats but also in: 1. Advanced-stage sporadic HGSCs associated with ovarian tumor masses 2. Rare cases of 1ry tubal or peritoneal HGSCs without obvious ovarian involvement 1. Piek JM, et al. J Pathol 2001;195(4): Callahan MJ, et al. J Clin Oncol 2007;25(25): Kindelberger DW, et al. Am J Surg Pathol 2007;31(2):161 9.
39 Early tumor progression within the fallopian tube and the resultant genetic profile of HG SOC.
40 Risk reducing interventions/procedures Procedure Risk Reduction of ovarian cancer Salpingo oophorectomy 71 96% Tubal ligation 18% Salpingectomy 70% Cortesi, L., A. Toss, and E. De Matteis. "Preventive Strategies for Ovarian Cancer." (2013), Rice, Megan S. et al, International Journal of Cancer(2013), Aderson et al. Int J Gynecol Cancer 2013
41 Take Home Messages Consider taking a comprehensive personal and family history Consider using a risk model to estimate the cancer risk (e.g. Claus model) Consider a medical oncology genetic counseling when it looks too complicated Consider testing when risk estimates are appropriate Discuss risk reducing surgeries Discuss implications on the patient herself and her family members
42 Conclusions 1. The science is rapidly developing: we are too slow 2. We all have to keep up
43
44
45
46
47 Do Salpingectomy.. Avoid Debulking?! Mohamad Kanso MED III
48 Serous epithelial cancer of the Ovary Most serious gynecological cancer Too late Diagnosis almost always 2013 The Clearity Foundation. All Rights R Pathogenesis is still unclear due to the lack of clearly identified carcinogenic sequence
49 New Studies Ovarian Cancer and Origins in the Fallopian Tubes, Linda Perrett, 20 Fallopian Tube Probable starting point for most serous ovarian
50 Two theories about EOC origin
51 1. Ovulation Theory:
52 Ovulation Scarring Deep Epithelial Invaginations Inclusion Cysts Mullerian Metaplasia Malignant transformation Due to stromal hormones and pro inflammatory cells
53 Epidemiological and Experimental arguments supporting this theory:
54 Protective Role of Oral Contraception Pregnancy Breast Feeding
55 Ovulation for > 35 years significantly higher RR of ovarian cancer
56 Forced to High ovulate prevale nce of Ovarian carcino ma Exponential relationship Number of between: ovulations & Malignant transformation
57 However As ovulation is a natural and physiological process Incriminating ovulation in the carcinogenesis of ovarian cancer Remains surprising, despite the facts described earlier.
58 Shifting the paradigm
59 2. Tubal Origin Theory
60 There is Convincing evidence that the distal Fallopian may be the commonest site of origin for HGSOC Herrington et al. The Journal of pathology (2010)
61 So the Tubal Theory is
62 Dysplastic tubal abnormalities TP53 mutations Genotoxic stress on secretory cells STIC (Serous Tubal Intraepithelial Carcinoma) Clonal expansion Progressive loss of control of cell control cycle Extension by anatomical proximity to ovary by endosalpingiosis
63 Supporting the tubal theory 1) Malignant tumors: found in the oviduct Fathalla Experimental data 2) STICs in prophylactic salpingo oophorectomies in BRCA patients Quick, Charles M., et al Modern Pathology (2011)
64 3) Overexpression of RSF 1, Cyclin E, p16, FASN and Stathmin 1 in both HGSOC and STICs 2011 Karst AM, Levanon K, Duraisamy S, et al. Gynecologic Oncology
65 4) STICs present in 61% in a series of HGSC of ovarian origin Przybycin et al. American Journal of Surgical Pathology (2010)
66 5)Other series of sporadic serous ovarian cancer were analyzed: STICs: 30 50%
67 6) Ovarian and Fallopian mucosal Carcinoma Shows similar copy number changes (FISH analysis) Possible Monoclonal Origin
68 Still Research could not yet confirm that the tube is the origin of Ovarian cancer
69 But what really matters is How could we reduce the risk of EOC?
70 Sudden decrease In estrogen PREMATURE MENOPAUSE night sweats, sleep disturbance, hot flashes, vaginal dryness, dyspareunia, and loss of sex drive.
71 2 Tubal Ligation? Risk reduction: 18% Strongest effects: in endometrioid tumors women who underwent the procedure after the last childbirth Rice, Megan S. et al, International Journal of Cancer(2013)
72 3 Salpingectomy? Estimated risk reduction: 70 % BS: greater protection than ligation Completely eliminating communication between the uterus and ovary Prevent ascending cancer cells or carcinogens Aderson et al. Int J Gynecol Cancer 2013
73 Bilateral Salpingectomy + TLH : Preservation of Ovarian function No perioperative complication May be used as a method for sterilization Morelli, Michele, et al. Gynecologic oncology(2013).
74 Conclusion The idea of tubal origin is still growing Clinicians and scientists prepared to take action But.. how to proceed? Trial may not be feasible An International prospective observational study might be the only hope
Ovarian Cancer Causes, Risk Factors, and Prevention
Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing f BRCA1 and BRCA2 Genes MP9478 Covered Service: Pri Authization Required: Additional Infmation: Yes when meets criteria below Yes--as shown below Pre and post-test genetic counseling is
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationHereditary Cancer Update Strengthening Linkages Workshop April 22, 2017
Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics
GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review
More informationGenetic Determinants, Risk Assessment and Management
Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon
More informationHereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com
Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic
More informationHereditary Cancer Update: What do GPOs need to know?
Hereditary Cancer Update: What do GPOs need to know? Mary McCullum, RN, MSN, CON(C) Nurse Educator, Hereditary Cancer Program BC Cancer Agency October 1, 2016 Conflict of Interest Disclosure Nothing to
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013
Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More informationMultigene Panel Testing for Hereditary Cancer Risk
Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program I have nothing to disclose Key Recommendations
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationGEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics
GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationA Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is
More informationCarol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center
Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Following this presentation you will be able to: Identify cancer survivors in your practice who might benefit from genetic counseling
More informationCancer Genomics 101. BCCCP 2015 Annual Meeting
Cancer Genomics 101 BCCCP 2015 Annual Meeting Objectives Identify red flags in a person s personal and family medical history that indicate a potential inherited susceptibility to cancer Develop a systematic
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationGenetic Panel Testing and Implications for Cancer Care
Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016
More informationpatient education Fact Sheet
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations OCTOBER 2017 BRCA1 and BRCA2 Mutations Cancer is caused by several different factors. A few types of cancer run in families. These types are
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationDisclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%
Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and
More informationObjectives. Case Study #1 1/28/14. A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice
A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice Heather Hampel, MS, CGC Associate Director, Division of Human Genetics Professor, Department of
More informationHereditary Cancer Products
Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationCorporate Medical Policy Genetic Testing for Breast and Ovarian Cancer
Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationObjectives. Genetics in Cancer Treatment and Prevention. Genes
Objectives Genetics in Cancer Treatment and Prevention Cheryl LaFlore, ARNP, MSN, BC Understand how to integrate genetic and genomic information into oncology nursing practice Define the role of an oncology
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationOBJECTIVES 8/25/2017. An attempt to organize the chaos
High Risk for Breast Cancer and Genetics: Who? What? Where? When? An attempt to organize the chaos Presented at Winds of Change Conference November 3, 2017 by Carol Hager, MSN, CRNP and Allison Haener,
More informationInherited Ovarian Cancer Diagnosis and Prevention
Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics
More informationBiology Response Controversies and Advances
Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER
More informationTHE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES
THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES Denise Uyar, MD Associate Professor OB/GYN Chief Gynecologic Oncology Medical College of Wisconsin April 12, 2019 NO DISCLOSURES
More informationUtilization of BRCA Testing. Breast and Ovarian Cancer in Texas
Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch
More informationSimple But Complicated: Genetic Testing in Hereditary Gynecologic Cancers
Simple But Complicated: Genetic Testing in Hereditary Gynecologic Cancers Robert Resta, MS, Licensed/Certified Genetic Counselor, Hereditary Cancer Clinic, Swedish Medical Center, Seattle, WA Nota Bene
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationExpert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian
Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian ANNOUNCER OPEN: Welcome to CME on ReachMD. This segment, entitled Inherited Susceptibility to Cancer: What Do Primary Care Providers
More informationAdvice about familial aspects of breast cancer and epithelial ovarian cancer
Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals FEBRUARY 2006 These guidelines contain three parts: 1. Information for health professionals
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationSo, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.
Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer
More informationGenetic counseling and testing. Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel
Genetic counseling and testing Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau, honoraria, consultancy Astra
More informationGenetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP
Genetics and Cancer Care Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP Faculty/Presenter Disclosure Faculty: Cynthia Forster-Gibson Relationships with commercial interests:
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective
More informationGENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2
GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2 Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationpatient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime types
More informationGenetic testing and pancreatic disease
Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationGENETIC TESTING FOR HEREDITARY CANCER
UnitedHealthcare Oxford Clinical Policy GENETIC TESTING FOR HEREDITARY CANCER Policy Number: DIAGNOSTIC 004.27 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationGenetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania
Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationOvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer
patient guide OvaNext genetic testing for hereditary breast, ovarian, and uterine cancer Because knowing your risk can mean early detection and prevention About half of the women diagnosed with uterine
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationPolicy and Procedure. Department: Utilization Management. SNP, CHP, MetroPlus Gold, Goldcare I&II, Market Plus, Essential, HARP
Retired Date: Page 1 of 9 1. POLICY DESCRIPTION: BRCA 1&2 Genetic Testing 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy, Claim
More informationUnderstanding Your Positive Result. A guide to understanding your risk and taking action
Understanding Your Positive Result A guide to understanding your risk and taking action 2017 Myriad Genetics, Inc. 320 Wakara Way, Salt Lake City, Utah 84108 PH: 1-800-469-7423 FX: 801-584-3615 1 PART
More informationDr Marion Harris (Medical Oncologist)
Dr Marion Harris (Medical Oncologist) 1. Cancer genetic testing and surveillance for familial breast and colorectal cancer What does an FCC do? Collect, assess and VERIFY a FHx of cancer Questionnaire
More informationUse of panel tests in place of single gene tests in the cancer genetics clinic
Clin Genet 2015: 88: 278 282 Printed in Singapore. All rights reserved CLINICAL GENETICS doi: 10.1111/cge.12488 Short Report se of panel tests in place of single gene tests in the cancer genetics clinic
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationHereditary Aspects of Pancreatic Cancer
Pancreatic Cancer Seminar San Francisco, CA Hereditary Aspects of Pancreatic Cancer Genetic Risk Assessment and Counseling for Familial Pancreatic Cancer February 3, 2016 Amie Blanco, MS, CGC Gordon and
More informationJill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania
Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Aging Family history Early menarche Late menopause Nulliparity Estrogen / Progesterone use after menopause More than two alcoholic
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationGenetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:
Genetics of Pancreatic Cancer October 6, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only: 1-408-435-7088
More informationTumori eredofamiliari: sorveglianza di donne ad alto rischio
Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed
More informationSo how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.
Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationImportance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC
Importance of Family History in Gynecologic Cancer Prevention Angela Thompson, MS, CGC Genetic Counselor Froedtert & The Medical College of Wisconsin Objectives Introduce role of genetic counselor Discuss
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationMP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
Medical Policy MP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk BCBSA Ref. Policy: 2.04.02 Last Review: 11/15/2018 Effective Date: 02/15/2019
More informationHBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.
HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify
More informationEligibility criteria for prophylactic treatment allowance
Eligibility criteria for prophylactic treatment allowance Southern Cross will only pay the prophylactic treatment allowance for the following healthcare services when the applicable eligibility criteria
More informationBe Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.
Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Hereditary cancer and you Approximately 5% to 10% of all cancers develop because a person inherited a genetic
More informationYes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationClinical Cancer Genetics
Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional
More informationWhat You Need to Know About Ovarian Cancer
What You Need to Know About Ovarian Cancer About Us The Rhode Island Ovarian Cancer Alliance (RIOCA) was formed in honor and memory of Jessica Morris. Jessica was diagnosed with Stage IIIC Ovarian Cancer
More informationGenetic Testing for Lynch Syndrome
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post-test genetic counseling is
More informationSurgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk
Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St
More information